Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2014

View Archived Issues

Baxter restructures agreement with Xenetic Biosciences and provides pipeline update

Researchers characterize antifungal activity EV-086

Glycopolymers used to uncover the mechanistic basis of tumor immunoprotection

Pazopanib demonstrates activity in patients with germ cell tumors

Sorafenib activity limited in patients with germ cell tumors

Chugai Pharmaceutical presents highlights of fourth quarter 2013

Phase II/III trial of Stallergenes' house dust mite immunotherapy tablets meets primary endpoint

AstraZeneca completes purchase of Bristol-Myers Squibb's global diabetes business

Burnet Institute receives grant to evaluate HIV test

Portola enters second collaboration with Bayer and Janssen for andexanet alfa

Chinese researchers present novel acetylcholinesterase inhibitors for Alzheimer's disease

New chimeric proteins patented by Biogen Idec and Amunix Operating

Omeros reports data from phase I trial of OMS-721

Phase Ib trial evaluates ONT-380 in breast cancer

Yong Guang Pharmaceutical discloses novel agents for cancer

U.S. group claims new HDAC4 inhibitors for Huntington's disease

Scientists in China synthesize new CETP inhibitors

Grastek obtains approval in Canada for grass pollen-induced allergic rhinitis

Tecfidera obtains approval in Europe for multiple sclerosis

Agios Pharmaceuticals opts for U.S. rights to IDH1 program

U.S. Navy approves phase I trial of Multikine in patients with HIV/HPV and perianal warts

FDA grants breakthrough therapy designation to eltrombopag

Tetrandrine demonstrates ability to protect against Ebola virus challenge in vivo

Ferrer collaborates with Ergomed and Ildong Pharmaceuticals for lorediplon

Kyowa Hakko Kirin initiates phase III study of ARQ-197 for HCC in Japan

Dainippon Sumitomo Pharma offers overview of third quarter of fiscal 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...